Gilead Sciences Inc (GILD)

$129.58 -2.48 (-1.88%)
Market Cap 160.88B
Revenue (ttm) 29.44B
Net Income (ttm) 8.51B
EPS (ttm) N/A
PE Ratio 15.78
Forward PE N/A
Profit Margin 28.90%
Debt to Equity Ratio 0.95
Volume 6,641,000
Avg Vol 5,932,848
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 7%
Beta 0.31
Analysts Strong Sell
Price Target $159.38

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 522 5853
Address:
333 Lakeside Drive, Foster City, United States
MarketBeat
MarketBeat May. 17 at 1:05 PM
https://marketbeat.com/a/8660041/ $GILD Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
0 · Reply
Hooooooold
Hooooooold May. 15 at 7:09 PM
$GILD new here - why gilead been trending down past months?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 5:19 PM
$SLS SO MANY -- Inch THICK MILE WIDE Retail TOOLS.... Just the Secondary ASSET - SLS009 - already published Phase 2B Data for AML-MR patients at ASH, that is Better / longer Survival, no Safety Issues, than Magrolimab Phase 1B AML-MR Data - that $GILD paid $4.9B For / $27 Per SLS SHARE.... SLS is the Investment of Our Lifetimes.
0 · Reply
StockMomentumLab
StockMomentumLab May. 15 at 3:34 PM
BIOTECH OPEN TAPE (5/15): mixed red/green across the sector as catalysts drive early volatility and rotation.- 1 👉Click to view @StockMomentumLab for timely updates amid the volatility. $ZYME -1% buyback announced $NRIX -1% new Bex data in urticaria $GILD -1% $3B notes pricing $BLTE -2% Retina China oral data $TNYA -2% TN-401 interim data beats sentiment High volatility, data-driven moves dominating biotech flow out of the gate
0 · Reply
HedgeFollow
HedgeFollow May. 15 at 2:44 PM
. 🔍 𝗡𝗘𝗪 13𝗙 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 Top UAE Hedge Fund MUBADALA just filed their 13F. Most Notable Trades: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $SHOP 𝗗𝗢𝗨𝗕𝗟𝗘𝗗 position: $MU 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 60%: $GILD 𝗦𝗢𝗟𝗗 out: $DG Mubadala's portfolio is up 23.81% last quarter. Source: hedgefollow.com/funds/Mubadala+Investment+Co+PJSC
0 · Reply
focafoca99
focafoca99 May. 15 at 1:35 AM
$GILD priced $3 billion of senior unsecured notes across four tranches, with the offering set to close on May 20, 2026. https://www.rapidticker.com/news/gild-gilead-prices-3-billion-of-627359
0 · Reply
trenddetector
trenddetector May. 14 at 3:27 PM
$GILD Trodelvy (sacituzumab govitecan) is turning heads in triple-negative breast cancer and now bladder cancer. It's an antibody-drug conjugate — basically a smart missile that delivers chemo directly to cancer cells. Gilead's Trodelvy in combination with Merck's Keytruda showed a meaningful win in breast cancer at ASCO. Trodelvy is featured on YourCancerPath.com — a free cancer navigation site covering 22 cancer types. No login, no cost, just info. 🔗 YourCancerPath.com #GILD #breastcancer #Trodelvy
0 · Reply
mido89
mido89 May. 14 at 2:01 PM
$ATYR $GILD acquisition is near 😁🚀💶 1-2$
1 · Reply
skcots_13
skcots_13 May. 13 at 8:30 PM
$GILD sounds bullish to us. The Don has his point.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 13 at 7:41 PM
$SLS Investment Opportunity of a Lifetime. $SLS Just the ‘secondary’ asset SLS-009 is right now worth $27 per share. SLS009 Phase 2B AML-MR Trial data Published at ASH in December, is better than Magrolimab $FTSV Phase 1B AML-MR data published at ASH, that $GILD paid $4.9B for. - I've been here a while - if you're interested in money, scroll through my posts - lmk if you have any questions.
0 · Reply
Latest News on GILD
Gilead Prices $3 Billion of Senior Unsecured Notes

May 14, 2026, 9:21 PM EDT - 3 days ago

Gilead Prices $3 Billion of Senior Unsecured Notes

Gilead to present new data on PBC, viral hepatitis at EASL 2026

2026-05-13T15:45:42.000Z - 4 days ago

Gilead to present new data on PBC, viral hepatitis at EASL 2026

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

May 13, 2026, 8:30 AM EDT - 4 days ago

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 5:20 PM EDT - 5 days ago

Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026

Gilead price target lowered to $168 from $175 at Morgan Stanley

2026-05-10T14:47:24.000Z - 7 days ago

Gilead price target lowered to $168 from $175 at Morgan Stanley

Gilead price target raised to $157 from $155 at Truist

2026-05-08T15:05:33.000Z - 9 days ago

Gilead price target raised to $157 from $155 at Truist

Notable companies reporting after market close

2026-05-07T22:02:35.000Z - 10 days ago

Notable companies reporting after market close

ABNB AFRM AKAM ARLO COIN CRWV DBX

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

May 7, 2026, 4:39 PM EDT - 10 days ago

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead Sciences Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 10 days ago

Gilead Sciences Earnings Call Transcript: Q1 2026

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

May 7, 2026, 4:05 PM EDT - 10 days ago

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences Announces First Quarter Financial Results

May 7, 2026, 4:01 PM EDT - 10 days ago

Gilead Sciences Announces First Quarter Financial Results

Options Volatility and Implied Earnings Moves Today, May 07, 2026

2026-05-07T11:05:30.000Z - 10 days ago

Options Volatility and Implied Earnings Moves Today, May 07, 2026

ABNB COIN CRWV DKNG MCD RKLB SOUN

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

May 5, 2026, 2:40 PM EDT - 12 days ago

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

May 5, 2026, 6:01 AM EDT - 12 days ago

Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Can You Sue A Drug Company For Not Inventing Faster?

May 4, 2026, 5:15 AM EDT - 14 days ago

Can You Sue A Drug Company For Not Inventing Faster?

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 16 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV BMY GSK LLY

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

May 1, 2026, 6:00 AM EDT - 16 days ago

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

Gilead Sciences Transcript: AGM 2026

Apr 30, 2026, 1:00 PM EDT - 17 days ago

Gilead Sciences Transcript: AGM 2026

Gilead announces U.S. FDA accepted NDA submission for bictegravir, lenacapavir

2026-04-29T14:22:36.000Z - 18 days ago

Gilead announces U.S. FDA accepted NDA submission for bictegravir, lenacapavir

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Apr 29, 2026, 8:30 AM EDT - 18 days ago

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead completes acquisition of Arcellx for $115 per share in cash

2026-04-28T12:52:52.000Z - 19 days ago

Gilead completes acquisition of Arcellx for $115 per share in cash

ACLX

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Apr 28, 2026, 8:45 AM EDT - 19 days ago

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

ACLX

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Apr 27, 2026, 6:15 PM EDT - 20 days ago

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 22, 2026, 4:05 PM EDT - 25 days ago

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Arcus Biosciences discontinues Star-121 study with Gilead due to futility

2026-04-20T19:05:48.000Z - 27 days ago

Arcus Biosciences discontinues Star-121 study with Gilead due to futility

RCUS

Gilead receives all required regulatory approvals for Arcellx acquisition

2026-04-17T12:46:54.000Z - 4 weeks ago

Gilead receives all required regulatory approvals for Arcellx acquisition

ACLX

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Apr 17, 2026, 8:30 AM EDT - 4 weeks ago

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

Gilead announces investment in lenacapavir by PEPFAR, The Global Fund

2026-04-14T16:10:51.000Z - 4 weeks ago

Gilead announces investment in lenacapavir by PEPFAR, The Global Fund

PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

Apr 14, 2026, 12:00 PM EDT - 4 weeks ago

PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

Apr 13, 2026, 9:57 PM EDT - 4 weeks ago

Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Apr 10, 2026, 1:01 PM EDT - 5 weeks ago

AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Apr 9, 2026, 8:30 AM EDT - 5 weeks ago

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

TEM

Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise

Apr 9, 2026, 7:30 AM EDT - 5 weeks ago

Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise

Gilead Sciences Transcript: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 5 weeks ago

Gilead Sciences Transcript: M&A announcement

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Apr 7, 2026, 10:27 AM EDT - 5 weeks ago

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion

Apr 7, 2026, 9:14 AM EDT - 5 weeks ago

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Apr 7, 2026, 8:50 AM EDT - 5 weeks ago

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Apr 7, 2026, 8:30 AM EDT - 5 weeks ago

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead to acquire Tubulis GmbH for up to $5 billion

Apr 7, 2026, 8:23 AM EDT - 5 weeks ago

Gilead to acquire Tubulis GmbH for up to $5 billion

Gilead Extends Tender Offer to Acquire Arcellx

Apr 1, 2026, 4:13 PM EDT - 6 weeks ago

Gilead Extends Tender Offer to Acquire Arcellx

Markets Haven't Changed. These 2 Cheap Dividends Still Rule

Apr 1, 2026, 10:50 AM EDT - 6 weeks ago

Markets Haven't Changed. These 2 Cheap Dividends Still Rule

WM

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.

Mar 24, 2026, 8:03 AM EDT - 7 weeks ago

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

Mar 23, 2026, 6:55 PM EDT - 7 weeks ago

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

Mar 23, 2026, 6:28 PM EDT - 7 weeks ago

Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Mar 23, 2026, 6:15 PM EDT - 7 weeks ago

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports

Mar 23, 2026, 12:44 PM EDT - 7 weeks ago

Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports

5 Stocks to Buy in a High-Risk Bull Market

Mar 19, 2026, 2:15 PM EDT - 2 months ago

5 Stocks to Buy in a High-Risk Bull Market

AAPL C JCI PYPL

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GSK JNJ LLY

Gilead Sciences Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 11:00 AM EDT - 2 months ago

Gilead Sciences Transcript: Barclays 28th Annual Global Healthcare Conference

Gilead Sciences Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

Gilead Sciences Transcript: Leerink Global Healthcare Conference 2026

South Africa seeks local production of Gilead's HIV prevention drug

Mar 5, 2026, 1:02 AM EST - 2 months ago

South Africa seeks local production of Gilead's HIV prevention drug

Gilead Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

Gilead Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Mar 2, 2026, 8:30 AM EST - 2 months ago

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Johanna Mercier on Gilead's HIV prevention innovation

Feb 27, 2026, 2:30 PM EST - 2 months ago

Johanna Mercier on Gilead's HIV prevention innovation

Gilead's experimental HIV treatment shows low discontinuation rates in studies

Feb 25, 2026, 2:27 PM EST - 2 months ago

Gilead's experimental HIV treatment shows low discontinuation rates in studies

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Feb 25, 2026, 1:44 PM EST - 2 months ago

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Gilead Sciences to Present at Upcoming Investor Conferences

Feb 23, 2026, 4:05 PM EST - 2 months ago

Gilead Sciences to Present at Upcoming Investor Conferences

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

Feb 23, 2026, 8:41 AM EST - 2 months ago

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

ACLX

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Feb 23, 2026, 7:52 AM EST - 2 months ago

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

ACLX

Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout

Feb 23, 2026, 7:13 AM EST - 2 months ago

Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Feb 23, 2026, 6:36 AM EST - 2 months ago

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

ACLX

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.

Feb 23, 2026, 6:34 AM EST - 2 months ago

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.

Gilead to acquire Arcellx for $7.8 billion

Feb 23, 2026, 6:08 AM EST - 2 months ago

Gilead to acquire Arcellx for $7.8 billion

ACLX

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

Feb 23, 2026, 6:01 AM EST - 2 months ago

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

ACLX

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

Feb 23, 2026, 6:01 AM EST - 2 months ago

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

ACLX

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

Feb 17, 2026, 8:30 AM EST - 3 months ago

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

MarketBeat
MarketBeat May. 17 at 1:05 PM
https://marketbeat.com/a/8660041/ $GILD Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
0 · Reply
Hooooooold
Hooooooold May. 15 at 7:09 PM
$GILD new here - why gilead been trending down past months?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 5:19 PM
$SLS SO MANY -- Inch THICK MILE WIDE Retail TOOLS.... Just the Secondary ASSET - SLS009 - already published Phase 2B Data for AML-MR patients at ASH, that is Better / longer Survival, no Safety Issues, than Magrolimab Phase 1B AML-MR Data - that $GILD paid $4.9B For / $27 Per SLS SHARE.... SLS is the Investment of Our Lifetimes.
0 · Reply
StockMomentumLab
StockMomentumLab May. 15 at 3:34 PM
BIOTECH OPEN TAPE (5/15): mixed red/green across the sector as catalysts drive early volatility and rotation.- 1 👉Click to view @StockMomentumLab for timely updates amid the volatility. $ZYME -1% buyback announced $NRIX -1% new Bex data in urticaria $GILD -1% $3B notes pricing $BLTE -2% Retina China oral data $TNYA -2% TN-401 interim data beats sentiment High volatility, data-driven moves dominating biotech flow out of the gate
0 · Reply
HedgeFollow
HedgeFollow May. 15 at 2:44 PM
. 🔍 𝗡𝗘𝗪 13𝗙 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 Top UAE Hedge Fund MUBADALA just filed their 13F. Most Notable Trades: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $SHOP 𝗗𝗢𝗨𝗕𝗟𝗘𝗗 position: $MU 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 60%: $GILD 𝗦𝗢𝗟𝗗 out: $DG Mubadala's portfolio is up 23.81% last quarter. Source: hedgefollow.com/funds/Mubadala+Investment+Co+PJSC
0 · Reply
focafoca99
focafoca99 May. 15 at 1:35 AM
$GILD priced $3 billion of senior unsecured notes across four tranches, with the offering set to close on May 20, 2026. https://www.rapidticker.com/news/gild-gilead-prices-3-billion-of-627359
0 · Reply
trenddetector
trenddetector May. 14 at 3:27 PM
$GILD Trodelvy (sacituzumab govitecan) is turning heads in triple-negative breast cancer and now bladder cancer. It's an antibody-drug conjugate — basically a smart missile that delivers chemo directly to cancer cells. Gilead's Trodelvy in combination with Merck's Keytruda showed a meaningful win in breast cancer at ASCO. Trodelvy is featured on YourCancerPath.com — a free cancer navigation site covering 22 cancer types. No login, no cost, just info. 🔗 YourCancerPath.com #GILD #breastcancer #Trodelvy
0 · Reply
mido89
mido89 May. 14 at 2:01 PM
$ATYR $GILD acquisition is near 😁🚀💶 1-2$
1 · Reply
skcots_13
skcots_13 May. 13 at 8:30 PM
$GILD sounds bullish to us. The Don has his point.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 13 at 7:41 PM
$SLS Investment Opportunity of a Lifetime. $SLS Just the ‘secondary’ asset SLS-009 is right now worth $27 per share. SLS009 Phase 2B AML-MR Trial data Published at ASH in December, is better than Magrolimab $FTSV Phase 1B AML-MR data published at ASH, that $GILD paid $4.9B for. - I've been here a while - if you're interested in money, scroll through my posts - lmk if you have any questions.
0 · Reply
HedgeFollow
HedgeFollow May. 13 at 3:52 PM
🔍 𝗡𝗲𝘄 13𝗙 𝗥𝗲𝗹𝗲𝗮𝘀𝗲𝗱 🔎 Outstanding Hedge Fund Ensign Peak just filed their 13F for Q1. Most notable position changes: 𝗔𝗱𝗱𝗲𝗱 20-40% 𝗺𝗼𝗿𝗲: $CRM , $GILD , $MRK 𝗗𝗢𝗨𝗕𝗟𝗘𝗗 position: $BSX 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 40%: $ABBV Ensign portfolio is up 82% in past 3 years Source: https://hedgefollow.com/funds/Ensign+Peak+Advisors
0 · Reply
cloudhedge
cloudhedge May. 13 at 2:38 PM
At the BofA conference, $GILD stated that Immunology & Inflammation (I&I) has been established as the company’s third core strategic pillar. This focus has been reinforced by the recent acquisition of Ouro Medicines. Management noted that Ouro previously focused on B-cell biology in autoimmune diseases, and views TCEs as a promising approach for achieving sustained responses and potential disease remission. GILD indicated that gamgertamig could enter registrational development in 2027. Near-term I&I catalysts also include IRAK4 data in lupus and updates on an oral α4β7 program in IBD in the second half of the year. While the I&I pipeline remains early-stage, the company continues to build capabilities in this area with potential for platform expansion over time. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!
0 · Reply
focafoca99
focafoca99 May. 13 at 12:40 PM
$GILD showcasing new PBC and hepatitis delta data at EASL 2026. https://www.rapidticker.com/news/gild-gilead-to-present-new-data-bbb710
0 · Reply
itsfloridaking
itsfloridaking May. 13 at 1:44 AM
$GILD 🧬
0 · Reply
Jblack500
Jblack500 May. 12 at 4:30 PM
$GILD that 128 level has held very well
0 · Reply
itsfloridaking
itsfloridaking May. 12 at 4:12 PM
$GILD easiest hold EVER 🤴🫴
0 · Reply
itsfloridaking
itsfloridaking May. 12 at 4:12 PM
$GILD he’s still waiting btw
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 12 at 4:48 AM
$SLS Just the ‘secondary’ asset is right now worth $27 per share. 009 P2B Aml-mr data published at Ash is better than Magrolimab p1B Aml-mr data published at Ash, that $GILD paid $4.9B for.
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 3:07 PM
$GILD Current Stock Price: $133.85 Contracts to trade: $134.0 GILD May 15 2026 Call Entry: $2.00 Exit: $3.15 ROI: 58% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
itsfloridaking
itsfloridaking May. 11 at 2:02 PM
$GILD up 1.63% since this post btw
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 11 at 1:59 PM
$KYTX 5. Partnership or strategic interest hints This is where the speculative fireworks will happen. Big Pharma is aggressively moving into autoimmune and cell therapy: • $RHHBY • $BMY • $ABBV • Novartis • $GILD The entire sector is watching autoimmune CAR-T closely. Kyverna recently strengthened commercial leadership hiring ahead of launch preparation. A bullish earnings call could hint at: • strategic partnership discussions • manufacturing collaborations • commercialization support • regional licensing • or even inbound acquisition interest Even subtle language will ignite biotech momentum. 💲🔥💲🔥💲
0 · Reply
DonCorleone77
DonCorleone77 May. 10 at 5:12 PM
$GILD Gilead price target lowered to $168 from $175 at Morgan Stanley Morgan Stanley lowered the firm's price target on Gilead to $168 from $175 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q1 report.
0 · Reply